Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

Canadian Cancer Trials Group MDC.1 (SWOG S1117) study - A Randomized Phase II Study of Azacitidine in Combination With Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) - was centrally activated on November 22, 2012.

The objectives of this trial are to:
  • Test whether the response rate (complete remission, partial remission, or hematologic improvement) of patients with higher-risk MDS or CMML who receive either the combination of lenalidomide and azacitidine or the combination of vorinostat and azacitidine is improved compared to patients who receive single-agent azacitidine;
  • Estimate relapse-free survival, overall survival and cytogenetic response rate of patients treated on each regimen;
  • Estimate the frequency and severity of toxicities of the three regimens in this patient population;
  • Investigate in a preliminary manner the frequency of subgroups from prestudy cytogenetic studies and correlate these subgroups with clinical outcomes in this patient population; and,
  • Collect specimens for banking for use in future research studies.
If you are interested in participating in this trial or have any questions, please contact Gail McDonald, Study Coordinator, at 613-533-6430 or